Premium
Same day outpatient transjugular liver biopsies in haemophilia
Author(s) -
Saab S.,
Cho D.,
Quon D. V. K.,
Ibrahim A. B.,
Dong P.,
Marder V.,
Logan L.
Publication year - 2004
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2004.01043.x
Subject(s) - medicine , haemophilia , liver biopsy , perioperative , biopsy , surgery , blood transfusion , outpatient clinic , liver disease , haemophilia a , hepatitis c , pegylated interferon , complication , gastroenterology , chronic hepatitis , immunology , virus , ribavirin
Summary. Patients with haemophilia are at increased risk of hepatitis C infection because of prior transfusion of blood products. Virtually all haemophiliacs who received pooled blood products before the mid‐1980s have been infected with hepatitis C. A liver biopsy is important to identify the extent of liver disease, and to help determine the necessity of interferon therapy. With factor replacement, in‐hospital liver biopsy is safe. Thirty patients with haemophilia were evaluated for chronic hepatitis C infection. Eleven patients subsequently underwent successful transjugular liver biopsy in the outpatient setting after appropriate factor replacement. Mean ± SD pre‐ and posthaemoglobin values were 15.8 ± 0.79 and 14.4 ± 0.71 g dL −1 ( P = ns ). There was no significant change in heart rate, systolic or diastolic blood pressure during the monitoring period ( P = ns ) and no major complication was noted in perioperative follow‐up. The mean length of the liver biopsy specimens was 1.7 ± 0.3 cm, mean grade was 2 ± 0.6 and mean stage was 2.3 ± 1.2. Our experience demonstrates that outpatient transjugular liver biopsy can be safely performed in patients with haemophilia in the outpatient setting, avoiding the cost and need for hospital admission.